Page 1

CASTLE BIOSCIENCES NEWS RELEASE Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory 4/27/2021 PDF Version With the acquisition , Castle expects to make available the most comprehensive molecular testing offering for difficult - to - diagnose melanocytic lesions . The Company to host a conference call today at 7:30 a.m. E.T. FRIENDSWOOD , Texas -- ( BUSINESS WIRE ) -- Apr . 27 , 2021-- Castle Biosciences , Inc. ( Nasdaq : CSTL ) , a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions , today announced it has signed a definitive agreement to acquire all of the equity of Myriad myPath , LLC ( Myriad myPath Laboratory ) , from Myriad Genetics . Myriad myPath Laboratory is a CLIA - certified laboratory in Salt Lake City , where the myPath Melanoma 23 - gene expression profile ( GEP ) test was developed and is currently owned and offered . Castle is acquiring Myriad myPath Laboratory for $ 32.5 million . Castle will finance the acquisition price with cash and cash equivalents on hand . The transaction is expected to close approximately four weeks post signing , at which time Castle will be the successor owner of Myriad myPath Laboratory . The transaction is subject to customary conditions to closing . myPath Melanoma is a clinically validated GEP test designed to be used as an adjunct to histopathology when the distinction between a benign nevus and a malignant melanoma cannot be made confidently by histopathology alone . Castle currently offers DecisionDx® DiffDxTM - Melanoma , a 35 - GEP test designed to characterize difficult - to- diagnose melanocytic lesions . myPath Melanoma is a distinct test , which Castle anticipates will complement its current offerings and enable Castle to provide the most comprehensive molecular testing solution for difficult - to- 1